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Hepatocellular carcinoma (HCC) is globally the second most common cause of cancer mortality. The majority of HCC
patients are diagnosed at advanced stage disease for which no curative treatments exist. TGF-β has been identified as a
potential therapeutic target. However, the molecular mechanisms mediating its functional switch from a tumor
suppressor to tumor promoter inHCC and its interactionswith other signaling pathways are poorly understood. Here,we
demonstrate an aberrantmolecular network between the TGF-β and c-KIT pathway thatmediates the functional switch of
TGF-β to a driver of tumor progression in HCC. TGF-β/SMAD2 signaling transcriptionally regulates expression of the c-KIT
receptor ligand (stemcell factor [SCF])with subsequent auto- andparacrine activationof c-KIT/JAK1/STAT3signaling. SCF
induces TGF-β1 ligand expression viaSTAT3, thereby forming a positive feedback loop betweenTGF-β/SMADandSCF/c-
KIT signaling. ThisnetworkneutralizesTGF-β–mediatedcell cycle inhibitionand induces tumor cell proliferation, epithelial-
to-mesenchymal-transition, migration, and invasion. Disruption of this feedback loop inhibits TGF-β tumor-promoting
effects and restores its antiproliferative functions. Consistent with our in vitro data, we demonstrate SCF overexpression
and its correlation to SMAD2 and STAT3 activation in humanHCC tumors, advanced tumor-node-metastasis stages, and
shorter survival. CONCLUSIONS: Canonical TGF-β and c-KIT signaling forms a positive, tumor-promoting feedback loop.
Disruption of this loop restores TGF-β tumor suppressor function and provides the rationale for targeting the TGF-β/SCF
axis as a novel therapeutic strategy for HCC.
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Hepatocellular carcinoma (HCC) is globally the second most
common cause of cancer-related mortality [1]. More than 70% of
HCCs are diagnosed at advanced stages not amenable to curative
treatments. The multikinase inhibitor sorafenib is the only systemic
agent that has demonstrated a survival benefit in advanced-stage
HCC that is limited to 2 to 3 months [2]. Novel molecular targeted
agents failed to improve outcomes [3]. A better understanding of the
molecular signaling networks regulating HCC biology is indispens-
able for the development of novel therapeutic strategies.
TGF-β signaling through SMAD proteins, known as canonical
TGF-β signaling, is a potent tumor suppressor pathway. It is activated
through binding of the ligand TGF-β to its cognate receptor resulting
in serine phosphorylation and nuclear translocation of transcription
factors SMAD2/3. Transcriptional responses to TGF-β are cell type
and context specific. Inactivation of TGF-β/SMAD signaling
promotes hepatocarcinogenesis [4,5]. Paradoxically, TGF-β1 serum
concentrations are elevated in HCC patients and correlate with
disease extent and shortened survival [6]. The functional switch of
TGF-β to a tumor promoter has been observed in other malignancies;
the underlying mechanisms are tumor type specific [7]. TGF-β
receptor inhibitors for HCC are being explored in clinical trials, but
the mechanisms mediating the TGF-β dysregulation in HCC are
poorly understood [8].
c-KIT signaling is initiated through binding of the c-KIT ligand stem
cell factor (SCF) to the c-KIT receptor resulting in PI3K/AKT, SRC, and
JAK/STAT activation [9]. SCF plays a key role in hepatic regeneration
after hepatic injury [10,11]. However, SCF expression in HCC and its
role in HCC tumor progression are unknown. Moreover, interactions
between TGF-β and c-KIT signaling have not been described.
We aimed to determine the HCC-specific molecular mechanisms
mediating TGF-β dysregulation to a driver of tumor progression and
characterize the molecular network between TGF-β and c-KIT signaling.
Materials and Methods
Cell Lines and Culture
Human liver tumor cell lines HepG2 (ATCC, Cat. #HB-8065),
SNU398 (ATCC, Cat. #CRL-2233), and SNU449 (ATCC, Cat.
#CRL-2234) were cultured under standard conditions in Dulbecco’s
modified Eagle’s medium, and Hep3B (ATCC, Cat. # HB-8064) in
modified Eagle’s medium (10% FBS, penicillin G [100 U/ml],
streptomycin [100 μg/ml]). Prior to cytokine treatment, cells were
serum starved for 12 hours followed by cytokine incubation under
serum-free conditions.
Stably Transduced Cell Lines
Fourth-generation lentiviral vector systems were used for stable
transduction with shRNA. Cells were selected with puromycin followed
by GFP-directed fluorescence-activated cell sorting. Knockdown was
confirmed by quantitative reverse transcriptase polymerase chain reaction
(qRT-PCR), immunoblot analysis, and/or enzyme-linked immunosor-
bent assay (ELISA).
Invasion Assay
Invasion assay was performed as previously described [12]. Invasion
was assessed after 48 hours using lightmicroscopic (40×) quantification in
three high-power fields (invasion [%] = [mean number of cells invading
through Matrigel-coated membrane/mean number of cells migrating
through uncoated insert membrane] × 100).Viability Assay
Cell viability was assessed by manual quantification andmethyl thiazol
phenyl tetrazoliumbromide (MTT) assay. Trypan blue–stained cells were
quantified using a hemocytometer. For MTT assay, the CellTiter 96
Non-Radioactive Cell Proliferation Assay (Promega, Cat. #G4000) was
used following the manufacturer’s recommendations.
BrdU Proliferation Assay
The BrdU cell proliferation assay kit (Cell Signaling Technology) was
used according to the manufacturer’s recommendations. Absorbance was
measured at 450 nM using Synergy H4 hybrid reader (BioTek).
Fluorescence-Activated Cell Sorting
PI-based fluorescence-activated cell sorting was performed as
previously described [13]. Cell cycle data analysis was performed
using FlowJo software.
Immunofluorescence
Following blocking (1% BSA, TBST), methanol-fixed cells were
incubated with primary antibodies overnight at 4°C. Subsequently,
cells were incubated with Alexa Fluor 488-/594-conjugated secondary
antibodies for 1 hour. Nuclei were stained with 4',6-diamidino-
2-phenylindole (DAPI) (1 μg/ml) for 20 seconds. Slides were
mounted with SlowFade (Cat. #S36939 Invitrogen) and analyzed by
fluorescent microscopy.
Immunoblot Analysis
Whole-cell lysates were analyzed by immunoblot analysis as
previously described [14].
ELISA
Human SCF Quantikine ELISA kit (R&D Systems, #DCK00) and
the Human TGF-β1 Quantikine ELISA kit (R&D Systems,
#DB100B) were used for cytokine quantification following the
manufacturer’s recommendations.
Chromatin Immunoprecipitation (ChIP)
ChIP-IT Express Enzymatic kit (Active Motif, #53008) was used
according to the manufacturer’s recommendations. Three micro-
grams of anti-SMAD2/3, anti-STAT3, or IgG antibody was used per
immunoprecipitation.
Transfection
Transfection was performed according to the manufacturer’s
recommendations using Lipofectamine 2000 (Invitrogen, #11668)
for Hep3B cells and Lipofectamine 3000 (Invitrogen, #L3000001)
for HepG2 cells.
Luciferase Assay
The luciferase expression vector system pRL-TK (Promega,
#E2241) was used for promoter analysis. Firefly and Renilla luciferase
activities were quantitated using the Dual Luciferase Reporter Assay
System (Promega, #E1910).
Microarray Analysis
Microarray data (GEO ID: GSE10186) were obtained from the
GEO database. Normalized data were used for detection of genes
associated with survival. Genes associated with survival were detected
through feature-by-feature Cox PHmodels in which the gene level was
analyzed as the independent variable and the survival status as the
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for subsequent Ingenuity Pathway Analysis to extract genes involved in
the TGF-β signaling pathway. Kaplan-Meier plots were generated for
identified genes in the TGF-β signaling pathway. In the Kaplan-Meier
plot for each specific gene, samples were divided into two (upregulation
and downregulation) groups using the median gene level as the cutoff.
A log-rank test was performed to compare the survival rates between
two groups.
Migration Assay
Cell migration was assessed using the in vitro scratch assay as
previously described [15]. At 0, 24, and 48 hours after cell layer
disruption, wound width was measured using Image J software.
TUNEL Assay
Cell apoptosis was evaluated by DeadEnd Colorimetric TUNEL
system (Promega) following the manufacturer’s recommendation.
Cells were counterstained with hematoxylin.
Immunohistochemistry
Tissue microarrays and the corresponding clinical information were
obtained from US Biomax (Cat. #LV8013) and Imgenex (Cat.
#IMH-318 and Cat. #IMH-360). Immunohistochemistry was
performed as previously described [14]. Immunohistochemical
staining was performed using VECTASTAIN Elite ABCKit Universal
(#PK-7200) and DAB (#SK-4100) substrate KIT (Vector Laborato-
ries, Burlingame, CA). Counterstain was performed with hematoxylin
(Vector Laboratories, #H-3404). Two methods were used for
quantification: 1) positivity defined as N30% of immunohistochemi-
cally positive tumor cells and 2) Allred scoring system [16] adapted for
intranuclear pTyr705STAT3, pSer465/467SMAD2, and cytosolic SCF.
Proportion of positive tumor cells (PS): 0%, 0 points; b1%, 1 point;
1% to 10%, 2 points; 11% to 33%, 3 points; 34% to 67%, 4 points;
and N67%, 5 points. Intensity score of positive tumor cells (IS): none,
0 points; weak, 1 point; intermediate, 2 points; and strong, 3 points.
The total score (TS) = PS + IS. Positivity was defined as TS of more
than 2.
Quantitative RT-PCR
Total RNA was extracted using RNAeasy kit (Qiagen, Cat.
#74124). cDNA was synthesized using the SuperScript II kit
(Invitrogen) and 1 μl added to Power SYBR Green PCR MasterMix
(BioRad Cat. #172-5260). Primers (Suppl. Table 1) were added to a
concentration of 400 nM. qRT-PCR was performed using the C100
Thermal Cycler (BioRad), and data were analyzed using BioRad CFX
Manager.
RNA extraction from human tumor tissue
Paraffin-embedded HCC tumor tissue was obtained through the
MD Anderson Cancer Center Pathology tissue bank. Studies were
approved by the MDACC Institutional Review Board (IRB
#PA13-0674). Tissues were reviewed and macrodissected by a
hepatobiliary pathologist (W. C. F.). For RNA extraction, the High
Pure RNA Paraffin Kit (Roche, #03270289001) was used according
to the manufacturer’s instructions.
Plasmid constructs
SCF- and TGFB-promoter fragments were amplified from genomic
DNA by PCR (Suppl. Table 1) and cloned into position of the BglII/
NheI-deleted promoter location of the psiCHECK-2 vector(Promega, #C8021). Plasmid DNA was amplified in DH5α
competent cells (Invitrogen, #18258-012) and isolated using Pure-
Link HiPure MaxiPrep Kit (Invitrogen, #K2100-07).
Reagents
TGF-β1 (#101-B1) and SCF (#255-SC-010) were from R&D
Systems; TGF-β1 was used at a concentration of 10 ng/ml and SCF at 5
ng/ml, unless otherwise specified. JAK inhibitor I (#420099) and c-Kit
inhibitor ISCK03 (#569615) were from EMDMillipore (Billerica, MA);
STATTIC (#573099) was fromTocris (Minneapolis, MN). Primers and
antibodies are summarized in Suppl. Tables 4 and 5.
Statistical Analysis
In vitro data represent at least three independent experiments using
cells from a minimum of three separate isolations and are expressed as
means ± standard deviations unless otherwise specified. Differences
between two groups were compared using 2-tailed Student’s t tests.
For patient data analysis, continuous variables were summarized using
descriptive statistics; categorical variables were tabulated with
frequency and percentage. Fisher’s exact test and Wilcoxon rank
sum test were used to compare categorical and continuous patient
characteristics between patients.Results
SMAD2-activation in HCC and Its Correlation to STAT3-
activation and Clinical Parameters
The status of TGF-β pathway constituents in HCC was analyzed
using transcriptomic data of 80 HCC patients (Oncomine database,
GEO: GPL5474). Using Cox regression analysis, we identified 342
genes associated with clinical outcomes (Suppl. Table 1). Ingenuity
Pathway Analysis of these genes demonstrated a correlation between
SMAD2 upregulation and SKI downregulation with reduced patient
survival (Suppl. Figure 1A). SKI protein inhibits canonical TGF-β
signaling through inhibition of SMAD2 phosphorylation and as a
transcriptional repressor [17,18]. Kaplan-Meier survival analysis
confirmed significantly decreased survival in patients with SMAD2
upregulation and SKI downregulation (Figure 1A). Subsequently, we
analyzed an independent set of matched nonmalignant hepatic and
tumor tissues of HCC patients (n = 27) for PAI-1, a transcriptional
target of TGF-β/SMAD signaling (Suppl. Figure 1B). PAI-1
expression was 3.33-fold (SEM ±0.77) higher in tumor versus
normal tissue (P b .0001).
To validate the correlation of TGF-β activation with clinical
outcomes, we evaluated nuclear pSer465/467SMAD2 as a surrogate
marker of canonical TGF-β signaling activation in HCC tumor
samples of an independent third set of 116 patients (Figure 1B;
patient’s characteristics summarized in Suppl. Table 2). SMAD2
activation was significantly higher in advanced HCC (stages III/IV)
than early-stage HCC (stages I/II) with a mean Allred score of 4.91
(SEM ±0.26) versus 3.53 (SEM ±0.30) (P = .0007) (Figure 1C).
Survival was significantly shorter in patients with pSer465/
467SMAD2-positive tumors (Suppl. Figure 1C).
JAK/STAT3 signaling has a key oncogenic role in hepatocarcino-
genesis and HCC tumor progression [19]. We evaluated STAT3
activation in the 116 HCC tumors previously evaluated for pSer465/
467SMAD2 (Figure 1B). Intratumoral pTyr705STAT3 levels were
considerably higher (P = .02) in advanced than in early-stage HCC
with a mean Allred score of 4.72 (SEM ±0.27) versus 3.74 (SEM ±
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JAK/STAT and TGF-β/SMAD2 signaling, intratumoral pSer465/
467SMAD2/pTyr705STAT3 co-positivity was evaluated (Figure 1E).Only 12% to 18% of pSer465/467SMAD2-negative tumors were
positive for pTyr705STAT3. However, 17% to 49% of pSer465/
467SMAD2-positive tumors were positive for pTyr705STAT3. Rates of
Neoplasia Vol. 18, No. 6, 2016 Tumor Progression in Advanced Primary Liver Cancer Rojas et al. 375pSer465/467SMAD2/pTyr705STAT3 co-positivity were higher in stages
III and IV with 49% and 45% than in stages I and II with 17% and
24%. Correlation analysis for pSer465/467SMAD2 and pTyr705STAT3
(Suppl. Figure 1D) revealed a correlation coefficient R = 0.51 (95%
confidence interval [CI] 0.28-0.68) in early-stage HCC (P = .0001) and
R = 0.72 (95% CI 0.58-0.82) in advanced-stage HCC (P b .0001).
Co-immunofluorescence identified intracellular pSer465/467SMAD2/p-
Tyr705STAT3 co-positivity in HCC tumors (Suppl. Figure 1E).
In summary, our results show intratumoral TGF-β/SMAD2
activation in advanced-stage HCC and its correlation with shortened
patient survival and STAT3-activation.
Mechanisms of TGF-β1-induced Tumor Progression in
Primary Liver Cancer
Physiologically, STAT3 is not a target of TGF-β/SMAD signaling.
Based upon the above described correlation between activated
STAT3 and SMAD2 in human HCC tumors, we evaluated the
association between the two signaling cascades in vitro. Importantly,
we found that TGF-β1 activated STAT3 only in human liver tumor
cells with functional SMAD-mediated TGF-β signaling (Figure 2A
and Suppl. Figure 2A). The TGF-β–mediated activation of STAT3
was predominantly observed in liver tumor cells with sustained
SMAD2 phosphorylation in response to TGF-β treatment, whereas
no Tyr705 phosphorylation of STAT3 was observed in cell lines non-
or only transiently responsive to TGF-β treatment in regard to
SMAD2 phosphorylation (Suppl. Figure 2B). To confirm canonical
TGF-β signaling as the STAT3-activating signaling axis, we evaluated
the effect of SMAD2 knockdown on TGF-β–induced STAT3
activation. SMAD2 knockdown abrogated TGF-β1–induced Tyr705
phosphorylation of STAT3 (Figure 2B and Suppl. Figure 2B).
To evaluate the functional relevance of TGF-β/STAT3 signaling,
we analyzed prooncogenic TGF-β effects [20,21] in parental versus
STAT3-knockdown liver tumor cells (Suppl. Figure 2C). TGF-β1
induced E-cadherin expression and membranous relocalization in
HepG2STAT3-KD and Hep3BSTAT3-KD cells but not their parental cell
lines (Figures 2, C and D, Suppl. Figure 2D). In parental cells,
TGF-β1 induced SNAIL1, ZEB1, TWIST, N-cadherin, and
vimentin, but STAT3 knockdown abrogated TGF-β1–induced
transcription of these epithelial-mesenchymal transition (EMT)
markers (Figure 2C and Suppl. Figure 2E). Unexpectedly, we
observed enhanced TGF-β1–induced TWIST transcription in
HepG2STAT3-KD cells, whereas it was abrogated in Hep3BSTAT3-KD.
Next, we assessed the effect of TGF-β1–induced STAT3 activation
on tumor cell migration and invasion, and the therapeutic efficacy of
pharmacologic STAT3 inhibition. Whereas TGF-β potently induced
liver tumor cell migration and invasion, this induction was prevented
by STAT3 inhibition (Figure 2, E and F).
Taken together, our results demonstrate that TGF-β activates
STAT3 in HCC; this aberrant activation appears to depend on
sustained SMAD signaling. The TGF-β/STAT3 signaling network
promotes EMT, migration, and invasion of human liver tumor cells.Figure 1. SMAD2 and STAT3 activation in human HCC. (A) Kaplan-M
SMAD2 and SKI expression. (B) Representative sections of stages I t
467SMAD2 (upper panel) and pTyr705STAT3 (lower panel). (C) Allr
467SMAD2-positive tumors of HCC patients (n=116); patient’s charac
system–based quantification of intranuclear pTyr705STAT3-positive
summarized in Suppl. Table 2. (E) Stage-dependent quantification for
HCC tumors (n= 116); immunohistochemical positivity defined as N3
pTyr705STAT3.AntiproliferativeFunctions ofTGF-β/SMADinPrimaryLiverCancer
TGF-β is a known tumor suppressor, but it paradoxically increased
cell viability in HepG2 and Hep3B cells. STAT3 inhibition
neutralized this paradox TGF-β1 effect (Figure 3A and Suppl. Figure
3A). TGF-β signaling elicits its tumor-suppressive effects largely by
induction of cell cycle arrest and/or apoptosis. However, HCC cells
are frequently resistant to TGF-β–induced apoptosis due to
overactivation of antiapoptotic signaling pathways [22,23]. Consis-
tent with previous reports [22–24], we did not observe significant
TGF-β–induced apoptosis in parental or STAT3-knockdown liver
tumor cells (Suppl. Figure 3B). However, TGF-β1 inhibited tumor
cell proliferation in HepG2STAT3-KD and Hep3BSTAT3-KD, but not
in HepG2 or Hep3B cells (Figure 3B). Cell cycle analysis revealed
that TGF-β–induced G1 cell cycle arrest was restored in HepG2-
STAT3-KD in comparison to the parental cell line (P = .049) (Table 1).
In Hep3BSTAT3-KD, TGF-β1 treatment resulted predominantly in
G2 cell cycle arrest compared with Hep3B (P = .006). Analysis of cell
cycle regulatory proteins (Suppl. Figure 3C) showed that TGF-β–
induced upregulation of p21WAF1/CIP1 was maintained in both liver
tumor cell lines but considerably enhanced by STAT3 inhibition in
Hep3B. Similarly, TGF-β–induced upregulation of p27WAF1/CIP1 in
HepG2 increased with STAT3 inhibition. Interestingly, TGF-β
induced cyclin D1 expression in HepG2, but this induction was
inhibited by STAT3 inhibition. TGF-β was recently shown to induce
G2/M-phase arrest in Hep3B via upregulation of the negative CDK1
inhibitor Wee1 and downregulation of survivin [25,26]. We did not
observe an effect of TGF-β on survivin expression in the presence or
absence of STAT3 inhibition in Hep3B cells. Whereas we observed
TGF-β–induced upregulation of Wee1, this upregulation was
inhibited by STAT3 inhibition. However, STAT3 inhibition
mediated TGF-β–induced downregulation of cyclin B1 expression.
In summary, TGF-β cell cycle inhibitory and antiproliferative
functions are neutralized in human liver tumor cells with aberrant
TGF-β–induced STAT3 activation but can be restored by STAT3
inhibition.
Molecular Interactions between TGF-β and c-KIT Signaling
in Primary Liver Cancer
To evaluate if TGF-β/SMAD2 induces STAT3 phosphorylation
through secondary kinases, we analyzed the effect JAK1 inhibition on
TGF-β1–induced STAT3 activation. Complete inhibition of
TGF-β–induced Tyr705 phosphorylation and nuclear translocation
of STAT3, without inhibition of SMAD2 phosphorylation, was
achieved by JAK1 blockade (Suppl. Figure 4, A and B).
In fetal liver cells and human acute megakaryoblastic leukemia
cells, the c-KIT ligand SCF activates JAK/STAT3 signaling via its
cognate receptor c-KIT [27]. Interestingly, we identified TGF-β–
induced/SMAD2-dependent SCF expression in human liver tumor
cells (Figure 4A and Suppl. Figure 4C).
To test whether TGF-β activated STAT3 predominantly via SCF/
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receptor inhibition reduced TGF-β–induced Tyr705 phosphorylation
of STAT3 (Suppl. Figure 4D) and prevented its nuclear translocation(Figure 4B). Similarly, SCF knockdown (Suppl. Figure 4E) prevented
TGF-β1–induced Tyr705 phosphorylation of STAT3 in liver tumor
cells (Figure 4C).
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Figure 3. TGF-β antiproliferative functions are neutralized in human liver tumor cells but can be restored by STAT3 inhibition. (A) Liver
tumor cell viability analysis after 48 hours of TGF-β1 stimulation (10 ng/ml) ± STAT3 inhibitor STATTIC (5 μM) using trypan blue
quantification. (B) BrdU assay of parental and polyclonal STAT3-knockdown liver tumor cells treated with TGF-β1 (10 ng/ml) for 12 and 24
hours. Results are shown as percent of untreated cells (mean ± SEM).
Table 1. Cell Cycle Analysis of TGF-β1–Stimulated Parental and STAT3-Knockdown Liver Tumor Cells.
PT STAT3KD
TGF-β − + P Value − + P Value
HepG2
Sub G1 1.6 (±2.8) 1.6 (±2.6) .973 2.0 (±2.1) 1.7 (±1.6) .839
G0/G1 47.8 (±16.3) 49.4 (±10.4) .896 45.8 (±14.4) 72.0 (±7.4) .049
S 20.9 (±14.1) 25.5 (±15.7) .727 15.9 (±6.3) 10.2 (±9.3) .435
G2/M 29.6 (±16.8) 23.6 (±3.4) .578 36.5 (±10.4) 16.2 (±8.1) .057
Hep3B
Sub G1 1.5 (±1.7) 2.8 (±3.9) .628 0.4 (±0.7) 0.7 (±1.1) .770
G0/G1 51.7 (±6.8) 48.1 (±4.9) .500 52.7 (±1.7) 27.0 (±2.6) b .001
S 15.9 (±7.8) 16.3 (±4.5) .952 20.7 (±4.6) 28.3 (±1.7) .058
G2/M 30.4 (±5.3) 32.7 (±5.0) .611 26.0 (±5.4) 44.0 (±1.9) .006
Cell cycle analysis of TGF-β1–stimulated (12 hours) parental versus polyclonal STAT3-knockdown HCC cell lines using Propidium Iodide (PI)-based fluorescence-activated cell sorting. Results represent
the mean ± SD from three independent experiments.
Figure 2. TGF-β1 activates STAT3 and drives tumor progression via STAT3. Human liver cancer lines were stimulated for 12 hours with
TGF-β1 (10 ng/ml). (A) Immunoblot analysis for TGF-β1 induced activation of SMAD2 and STAT3. (B) Immunoblot analysis for STAT3
activation in parental versus SMAD2-knockdown HepG2 and Hep3B cells. (C) Immunofluorescence analysis for EMT-related proteins
vimentin (red) and E-cadherin (green), and nuclear 4',6-diamidino-2-phenylindole (DAPI) stain (blue) in parental versus polyclonal
STAT3-knockdown Hep3B cells. (D) qRT-PCR analysis for TGF-β1–induced transcription of EMT markers in parental HepG2 and Hep3B
cells, and their polyclonal STAT3-knockdown derivatives. (E) Wound assay for TGF-β1–induced tumor cell migration in the presence or
absence of the STAT3 inhibitor STATTIC (5 μM). (F) Invasion assay for TGF-β1–induced tumor cell invasion in the presence or absence of
the STAT3 inhibitor STATTIC (5 μM).
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378 Tumor Progression in Advanced Primary Liver Cancer Rojas et al. Neoplasia Vol. 18, No. 6, 2016In summary, SMAD2-mediated TGF-β signaling transcriptionally
regulates c-KIT ligand expression, resulting in STAT3 activation via
auto- and paracrine stimulation of c-KIT/JAK1.
Molecular Mechanisms of TGF-β-regulated SCF-expression
TGF-β can regulate gene transcription via SMAD binding to
SMAD binding elements (SBE) within the promoter region of its
target genes [28]. We analyzed the SCF promoter-containing 2.4-kb
5′-flanking region of the SCF gene for the SBE motif 5′-AGAC-3′
[29] and identified seven putative SBE upstream of the SCF start
codon (Suppl. Figure 4F). ChIP assays confirmed TGF-β1–induced
SMAD2 binding to the SCF promoter in liver tumor cells
(Figure 4D). For validation, we generated luciferase expression
vectors regulated by the full-length SCF promoter or SCF promoter
deletion mutants (Suppl. Figure 4F). TGF-β1 stimulation induced
luciferase expression in liver tumor cells transfected with the
full-length SCF promoter; however, sequential deletion of SBE-con-
taining promoter sequences resulted in a gradual decrease in TGF-β–
induced luciferase expression (Suppl. Figure 4G).
To confirm SMAD2 specificity of SCF promoter regulation,
parental liver tumor cells and their SMAD2-knockdown derivatives
were transfected with the full-length SCF promoter luciferase
expression vector followed by TGF-β1 stimulation. Whereas
TGF-β1 induced luciferase expression in parental liver tumor cells,
this induction was abrogated by SMAD2 knockdown (Figure 4E).
Our data demonstrate that TGF-β regulates SCF expression
through direct transcriptional promoter activation via SMAD2
binding to SBE within the SCF promoter.
SCF-expression in human HCC and Its Correlation to Clinical
Parameters, SMAD2- and STAT3-activation
We analyzed SCF expression in the 116 HCC tumors analyzed
before for pSer465/467SMAD2 and pTyr705STAT3 (Figure 5A). SCF
was overexpressed at significantly higher rates in advanced versus
early-stage HCC with a mean Allred score of 5.38 (SEM ±0.28)
versus 3.54 (SEM ±0.40) (P = .0002) (Figure 5B). SCF expression
was correlated to pSer465/467SMAD2 (P = .007) and pTyr705STAT3
(P = .06), and clinically to stages T4 (P = .035), N1/Nx (P = .005),
and M1 (P = .010) (Suppl. Table 3). Median survival of patients (n =
86) with SCF-positive versus -negative tumors was 29 months versus
79 months (P = .09) (Suppl. Figure 5A).
To confirm a potential association between TGF-β/SMAD2 signaling
and SCF expression, we evaluated intratumoral pSer465/467SMAD2/SCF
co-positivity (Figure 5C). Only 7% to 25% of pSer465/467SMAD2-nega-
tive tumors were positive for SCF. However, 21% to 50% of p
Ser465/
467
SMAD2-positive tumors were co-positive for SCF. Rates of pSer465/
467SMAD2/SCF co-positivity were higher in stages III and IV with 42%
and 50% than in stages I and II with 21% and 26%. Correlation analysis
for pSer465/467SMAD2 and SCF identified a correlation coefficient R =
0.36 (95% CI 0.10-0.57) in early-stage HCC (P = .0081) and R = 0.43
(95% CI 0.21-0.66) in advanced-stage HCC (P = .0003). For validation,
we evaluated matching nonmalignant hepatic and tumor tissue of an
independent set of HCC patients (n = 36) by qRT-PCR. Consistent with
our immunohistochemical analysis, SCF levels were higher in advanced-
than early-stageHCC (P = .029) (Figure 5D). Correlation analysis for SCF
and PAI-1 mRNA (Figure 5E) showed a correlation coefficient R = 0.06
(95% CI −0.59 to 0.67) in early-stage HCC (P = .43) versus R = 0.84
(95% CI 0.49-0.96) in advanced-stage HCC (P = .0006). Intracellular
SCF/pSer465/467SMAD2 co-positivity was identified in 33%of tumor cellsin advanced- versus 19% in early-stage HCC (P = .002) (Figure 5, F and
G).
In summary, SCF is overexpressed in HCC, and its expression
correlates with advanced TNM stages and TGF-β/SMAD2 activa-
tion. In conjunction with our in vitro data, co-positivity for pSer465/
467SMAD2 and SCF is intratumoral and intracellular.
Formation of a Positive Feedback Loop between SCF and
TGF-β1 in Primary Liver Cancer
Regulation of TGF-β1 expression is cell type specific. TGF-β
autoregulation has been described, but its mechanisms are incompletely
understood [30]. To test if SCF is a key mediator of TGF-β1
autoregulation, we evaluated TGF-β1 autoregulation in HepG2,
Hep3B, HepG2SCF-KD, and Hep3BSCF-KD cells. Whereas TGF-β1
treatment induced TGF-β1 transcription in parental liver tumor cells,
SCF knockdown prevented TGF-β1–induced TGF-β1 transcription
(Figure 6A). Based upon our data on TGF-β1/SCF-induced STAT3
activation and the recently described STAT3 dependence of TGF-β1
expression during hepatic fibrogenesis [31], we evaluated STAT3 as a
mediator of SCF-induced TGF-β1 expression. SCF significantly induced
TGF-β1 ligand expression in parental liver tumor cells, but this induction
was abrogated by STAT3 knockdown (Figure 6B and Suppl. Figure 6A).
We analyzed the 5′-flanking region of the TGFB1 gene for the
STAT3 consensus binding motifs 5′-TT(N4)AA-3′ and
5′-TT(N5)AA-3′ [32]. We identified two putative STAT3-binding
sites upstream of the TGFB1 start codon at positions −4384/−4373
(STB-1) and −5365/−5357 (STB-2) (Suppl. Figure 6B). ChIP assays
demonstrated TGF-β1–induced STAT3 binding to STB-2 but not
STB-1 (Figure 6C). We cloned the STAT3 binding site–containing
genomic DNA fragments of the TGFB1 gene into the enhancer
position of a thymidine kinase promoter–regulated luciferase
expression plasmid (Suppl. Figure 6B). Following transfection of
these constructs in liver tumor cells, TGF-β1 induced luciferase
expression only with plasmids containing STB-2, whereas no activity
was observed with plasmids containing only STB-1 (Figure 6D).
To confirm SCF as a key inducer of STAT3-mediated TGF-β1
autoregulation, we performedChIP analysis forTGF-β1–induced STAT3
binding in parental and SCF-knockdown liver tumor cells. TGF-β1
induced STAT3 binding to STB-2 in parental HCC cells but not in
HepG2SCF-KD and Hep3BSCF-KD (Figure 6E). For confirmation, STB-2
STAT3 binding site–containing luciferase constructs were transfected into
parental and SCF-knockdown liver tumor cells. TGF-β1 treatment
resulted in luciferase expression in parental liver tumor cells but not in
HepG2SCF-KD and Hep3BSCF-KD (Suppl. Figure 6C).
In summary, SCF is the keymediator of TGF-β1 autoregulation in liver
tumor cells. TGF-β1/SCF-activated STAT3 binds to the STB-2 regulatory
element upstream of the TGFB1 gene resulting in its induction. Thereby,
TGF-β1 and SCF form a positive feedback loop in HCC (Figure 7A).
Disruption of the TGF-β/SCF Feedback Loop and Its
Therapeutic Potential
Based upon our previous results, we hypothesized that disruption
of the TGF-β/SCF signaling loop will inhibit TGF-β–driven tumor
progression and restore TGF-β antiproliferative functions in the
presence of functional SMAD signaling.
Tumor cell migration of SMAD2-, STAT3-, and SCF-knockdown
cells in the absence of treatment did not differ significantly compared
with the parental cell lines. However, TGF-β1 treatment significantly
induced tumor cell migration of parental liver tumor cells, whereas
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Figure 4. TGF-β transcriptionally regulates SCF expression followed by auto- and paracrine activation of c-KIT/JAK1/STAT3 signaling. HepG2 and
Hep3B were stimulated for 12 hours with TGF-β1 (10 ng/ml). (A) ELISA for SCF in the supernatant of TGF-β1–treated parental and
SMAD2-knockout liver tumor cells (mean ± SEM). (B) c-KIT dependence of TGF-β–induced STAT3 activation analyzed by immunofluorescence
analysis for pTyr705STAT3 following stimulationwithTGF-β1±c-KIT inhibitor ISCK03 (5μM). Thebargraphsbelowshowthepercent of cells in the
immunofluorescence analysiswith intranuclear pTyr705STAT3 accumulation (mean±SEMof five high-power fields). (C) Immunoblot analysis for
TGF-β1–induced STAT3 activation in parental versus polyclonal SCF-knockdown liver tumor cell lines (protein lysates of Hep3BSCF-KD clone 2
were run on the same gel but noncontiguous). (D) ChIP analysis for SMAD2 binding to the SCF promoter following TGF-β1 stimulation; SMAD2
binding to the PAI-1 gene was used as a positive control. (E) TGF-β1–induced (10 ng/ml, 24-hour stimulation) luciferase activity using SCF
full-length promoter-regulated luciferase expression plasmids transfected in parental versus SMAD2-knockdown HCC cells.
Neoplasia Vol. 18, No. 6, 2016 Tumor Progression in Advanced Primary Liver Cancer Rojas et al. 379
A)
Stage IVbStage IIIStage IIStage INormal
B)
SCF- SCF+
Stage I
Stage II
Stage III
Stage IV
pSer465/467Smad2-
46% 25%
22%37%
30% 7%
9% 23%
pSer465/467Smad2+
SCF- SCF+
8%
15%
21%
18%
21%
26%
42%
50%
C)
E)
0
10
20
30
40
Early stage Advanced stage
pS
M
AD
2/
SC
F 
co
-
po
sit
ive
 c
el
ls 
[%
]
p = 0.002DAPI pSMAD2 SCF Overlay
St
ag
e 
II
St
ag
e 
III
St
ag
e 
IV
St
ag
e 
I
D)
Early HCC Advanced HCC
0
2
4
6
8
10
p=0.0002
SC
F+
 H
CC
 tu
m
or
s 
[A
llre
d s
co
re]
F)
0
10
20
30
40
SC
F 
m
RN
A 
tu
m
or
 v
s 
no
rm
al
 
[fo
ld 
inc
rea
se
]
Early HCC Advanced HCC
p=0.029
G)
0 5 10 15
0
5
10
15
20
0 5 10 15 20
0
1
2
3
PAI-1PAI-1
SC
F
SC
F
Early stage HCC: Advanced stage HCC:
R=0.06
p=0.43
R=0.84
p=0.0006
380 Tumor Progression in Advanced Primary Liver Cancer Rojas et al. Neoplasia Vol. 18, No. 6, 2016SMAD2, STAT3, and SCF knockdown abrogated TGF-β1–induced
migration (Figure 7B).
Next, we assessed the effect of SMAD2, SCF, or STAT3 knockdown
on TGF-β–induced tumor cell invasion (Figure 7C). Interestingly, eventhough basal levels of tumor cell invasion were higher in HepG2STAT3-KD
and Hep3BSCF-KD cells, TGF-β1 induced tumor cell invasion only in the
parental cell lines. Knockdown of SMAD2, STAT3, or SCF resulted in
abrogation or inhibition of TGF-β–induced tumor cell invasion.
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after disruption of SMAD2, STAT3, or SCF (Figure 7D). Consistent
with our prior data, no significant antiproliferative effects were
observed with TGF-β1 treatment of parental HepG2 and Hep3B
cells. As expected, also no significant antiproliferative effects were
noted after TGF-β1 treatment of SMAD2-knockdown liver tumor
cells. However, TGF-β antiproliferative functions were restored in
liver tumor cells after STAT3 and SCF knockdown. Interestingly,
TGF-β1 elicited a strong antiproliferative effect even in genetically
modified cells with higher basal proliferation rates than their parental
cells (HepG2SCF-KD).
Our data show that inhibition of STAT3 and SCF can inhibit the
paradoxical tumor-promoting functions of TGF-β and restore its
antiproliferative functions. Whereas knockdown of SMAD2 prevents
TGF-β–induced tumor cell migration and invasion, it does not
restore its antiproliferative effects. This finding is in line with the
understanding of canonical TGF-β signaling as the major mediator of
TGF-β antiproliferative effects.Discussion
The multikinase inhibitor sorafenib is the only efficacious systemic
therapy, but its survival benefit is limited to 3 months [2]. Novel
targeted agents failed to achieve superiority or noninferiority in
comparison to sorafenib [33,34]. The TGF-β pathway has been
identified as a promising therapeutic target, and TGF-β type I
receptor inhibition for HCC is currently being evaluated in clinical
trials (NCT01246986, www.clinicaltrials.gov) [8]. However, the
molecular mechanisms mediating the functional switch of TGF-β in
HCC are poorly understood, and systemic TGF-β inhibition bears
risks such as induction of secondary malignancies [35]. TGF-β–
induced tumor suppression is mediated by its canonical, SMAD-me-
diated signaling axis whose inactivation promotes hepatocarcinogen-
esis [4,5]. Here, we demonstrate TGF-β/SMAD2 activation in
advanced HCC and its correlation with shortened patient survival.
Our data are supported by recent immunohistochemical and
transcriptomic studies demonstrating intratumoral TGF-β/SMAD2
activation in HCC animal models and in human HCC samples, and
its correlation with invasive tumor phenotypes [36–40]. Our in vitro
data confirm the tumor-promoting role of TGF-β in our liver cancer
model, and we show that the tumor-promoting role of TGF-β1 is
mediated by SMAD2-dependent STAT3 activation. In human tumor
samples of patients with advanced-stage HCC, we also find an
intratumoral and intracellular positive correlation of SMAD2 andFigure 5. SCF is overexpressed in advanced HCC and is correlated w
stage I to IV human HCC tissue immunohistochemically stained for S
tumors of HCC patients (n = 116); patient’s characteristics are sum
intratumoral pSer465/467Smad2/SCF co-positivity in human HCC tumo
tumor cells per tumor being positive for pSer465/467Smad2 and SCF. (D
tissue in an independent set of HCC patients (n = 36). Data were norm
tumor versus matching nonmalignant hepatic tissue; the blue line re
advanced- versus early-stage HCC (P= .029). (E) Correlation analysis f
line represents the trend line based upon linear regression analysis
correlated in advanced-stage HCC with a correlation coefficient R= 0.
I to IV HCC tumors evaluated by co-immunofluorescence for SCF and
tumors (n = 116) analyzed for intracellular SCF/pSer465/467SMAD2
co-positive tumor cells in pSer465/467SMAD2-positive tumors (medianSTAT3 activation. STAT3 is a key oncogenic transcription factor in
hepatocarcinogenesis and a mediator of metastatic spread and
chemotherapy-resistance of HCC cells [19,41]. TGF-β inhibits
STAT3 phosphorylation in intestinal epithelial cells, prostate
epithelial cells, acute myeloid leukemia blasts, and a murine
hepatocarcinogenesis model [42–45], indicating that the here-
described TGF-β/STAT3 network is specific for advanced-stage
HCC. Interestingly, we observed TGF-β–induced Tyr705 phosphor-
ylation of STAT3 only in liver cancer cells with sustained Ser465/467
phosphorylation of SMAD2. In several different cancer cell lines, the
antiproliferative functions of TGF-β depend on sustained SMAD2
phosphorylation [46–48]. In our liver cancer cell model, though, the
antiproliferative functions of TGF-β are neutralized despite sustained
SMAD2-phosphorylation. Similar to other groups [48,49], we find
induction of cyclin-dependent kinase inhibitors (i.e. p21WAF1/CIP1)
following prolonged incubation with TGF-β1. However, our data
also show upregulation of cyclin B1 in Hep3B cells and TGF-β1–
induced upregulation of cyclin D1 in HepG2 cells. STAT3-inhibi-
tion downregulates cyclin D1 and cyclin B1, and restores TGF-β–
induced cell cycle arrest in our liver cancer model. In human
mammary epithelial carcinoma cells and prostate carcinoma cells, it
was described that a relative increase of p21WAF1/CIP1 to cyclin D1
results in cell cycle arrest [50]. Hence, the paradox of prolonged
TGF-β1–induced SMAD2 phosphorylation but neutralized antipro-
liferative effects in our cell model might be explained by
STAT3-induced upregulation of cyclin D1 and cyclin B1—both
known transcriptional targets of STAT3 [51].
Several groups reported that malignant hepatocytes that survive
TGF-β–mediated cytotoxicity undergo EMT and acquire migratory
and invasive properties following the prolonged exposure to TGF-β
[8,36,52–55]. In a recent clinical phase 2 trial, it was reported that
TGF-β type I receptor inhibition reduces E-cadherin serum
concentrations [56]. Consistent with these data, we show that
TGF-β induces the transcription of EMT regulators and promotes
tumor cell migration and invasion in our liver cancer model. Our in
vitro data demonstrate that STAT3 inhibition inhibits TGF-β–
induced EMT, tumor cell migration, and invasion. Hence, our data
suggest that STAT3-targeted therapeutic strategies have the potential
to inhibit tumor-promoting effects of TGF-β and restore its tumor
suppressor function. STAT3 inhibitors and also agents targeting
STAT3-activating kinases (i.e., JAK1/2 and c-KIT) were found to be
well tolerated and safe in clinical phase 1 trials [57–59]. This
therapeutic approach—curtailing TGF-β’s tumor promoter effects
and restoring its tumor suppressor function—has several advantagesith pSMAD2 and decreased survival. (A) Representative sections of
CF. (B) Allred scoring system–based quantification of SCF-positive
marized in Suppl. Table 2. (C) Stage-dependent quantification of
rs (n = 116); immunohistochemical positivity defined as N30% of
) SCF transcription in tumor versus matching nonmalignant hepatic
alized for GAPDH and are shown as fold increase in SCFmRNA in
presents the median. SCF transcription was significantly higher in
or intratumoral PAI-1 and SCFmRNA in human HCC tumors. The red
. Intratumoral PAI-1 and SCF mRNA was significantly (P = .0006)
84 (95% CI 0.49-0.96). (F) Representative sections of human stages
pSer465/467SMAD2 co-localization. (G) Quantification of human HCC
co-positivity. Shown is the percentage of SCF/pSer465/467SMAD2
number of cells of five high-power fields per sample).
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382 Tumor Progression in Advanced Primary Liver Cancer Rojas et al. Neoplasia Vol. 18, No. 6, 2016over systemically blocking the TGF-β type I receptor. The potential
procarcinogenic effects could be avoided, and elevated TGF-β levels
in HCC patients could enhance tumor suppression as an endogenous
therapeutic agent. Similarly, Dooley et al. proposed in a recent review
article a therapeutic combination strategy aimed at restoration ofTGF-β–mediated cytostasis through interference with survival
signaling and activation of TGF-β signaling [60].
Mechanisms of STAT3 activation and regulation are cell type and
context specific. In preliminary studies using kinase inhibitor
approaches, receptor knockdown, and cytokine arrays, we ruled out
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cytokine IL-6 as mediators of TGF-β1–induced Tyr705 phosphor-
ylation of STAT3 (Suppl. Figure 7, A and B) in our liver cancer
model. Instead, we identify the c-KIT ligand SCF as the key mediator
of TGF-β1–induced STAT3 activation. TGF-β induces SCF
expression followed by auto- and paracrine activation of c-KIT/
JAK1/STAT3. Interestingly, TGF-β1 is an inhibitor of SCF
expression in myelogenous leukemia blasts and hematopoietic
progenitor cells [61,62], indicating that TGF-β1–induced SCF
expression is specific to liver cancers.
Our data demonstrate that TGF-β regulates SCF expression through
direct SMAD2binding to and subsequent activation of its promoter.Due
to the low DNA-binding affinity of SMAD2, SMAD-responsive
promoters frequently contain multiple SBE [28,29]. We identified
several SBE within the SCF promoter and demonstrate SMAD2 binding
to the SCF promoter. Consistent with observations in the PAI-1
promoter [63], we find decreasing promoter activity with decreasing
numbers of SBE. The SMAD2 specifity of this effect is demonstrated by
abrogation of TGF-β–induced SCF promoter activation with SMAD2
knockdown. It is likely that additional factors are involved, as SMAD
proteins achieve high affinity and selectivity through interaction with
other DNA-binding cofactors [28]. Therefore, a SMAD2-knockdown
approach was chosen to validate SMAD2 signaling as the mediator of
TGF-β–induced SCF expression, as the lack of such cofactors could result
in false-negative results even after restoration of SMAD2 activation (i.e.,
knock-in model with constitutively activated SMAD2). Studies to
identify DNA-binding cofactors aberrantly recruiting SMAD2 to the
SCF promoter are currently ongoing in our laboratory.
SCF is a critical mitogen for liver regeneration [10,11], but its
expression, regulation, and role in HCC are unknown. Our data
demonstrate SCF overexpression in HCC and its correlation with
advanced TNM stages and shortened patient survival. Consistent
with our in vitro data, we demonstrate the intracellular correlation
between pSer465/467SMAD2 and SCF in human HCC tumors. The
correlation of SCF overexpression with the T4, N1, andM1 status of
our patient population supports the in vivo relevance of our data and
the TGF-β/SCF axis as a mediator of TGF-β–mediated tumor
progression.
Recently, the need for precision medicine has been recognized to
improve outcomes of HCC patients [33,34]. However, the diagnostic
benefit of tumor-targeted liver biopsies is limited in HCC by its
tumor heterogeneity; noninvasive biomarkers to guide treatment have
not been identified [64]. TGF-β1 serum and urine concentrations are
elevated in patients with HCC and were found to be predictors of
poor outcomes [6,65]. Increased intratumoral SCF expression and
SCF serum concentrations were found in patients with ovarian and
primary peritoneal carcinoma [66]. Ongoing studies in our laboratoryFigure 6. c-KIT signaling is the mediator of TGF-β autoregulation
ligand transcription in parental and SCF-knockdown liver tumor cells
qRT-PCR for TGF-β1 ligand transcription in SCF-stimulated parenta
GAPDH. (C) ChIP analysis of TGF-β1–treated and untreated liver tumor
PCR using TGF-β specific primers for STB-1 and STB-2; STB-2 also se
24 hours) luciferase activity using luciferase expression plasmids w
Figure 6B) transfected in liver tumor cells. Construct (1) contains STB
contains STB-1 only. (E) ChIP analysis for TGF-β1–induced STAT3 bind
tumor cells.evaluate the diagnostic accuracy of TGF-β/SCF serum analysis to
identify subsets of patients whose liver tumors are driven by the
TGF-β/SCF/STAT3 axis, thereby providing a noninvasive way to
guide targeted therapies.
Recently, it was described that resistance to TGF-β cytotoxicity
was mediated by autocrine TGF-β synthesis in fetal rat hepatocytes
[67]. Whereas TGF-β autoregulation has been described, its
mechanisms are incompletely understood [30]. We characterize the
molecular mechanisms of TGF-β1 autoregulation in our liver tumor
model and identify SCF/c-KIT as the mediator of its autoregulation.
Our data show that TGF-β1/SCF induces STAT3 activation and
binding to a regulatory element upstream of the transcription
initiation site of TGFB1 where it acts as a critical regulatory element
for TGF-β1 expression. Based upon the location of the STAT3-
binding site in relation to the TGFB1 promoter, and the degree of
transcriptional induction following stimulation of the STAT3-
binding element, it is likely that STAT3 fulfills an enhancer function
in TGFB1 transcriptional regulation. Our data are supported by
recent observations of decreased TGF-β1 expression in IL-6−/− mice
and STAT3 dependence of IL-6–induced TGF-β1 expression in
hepatocytes [31,68].
In summary, our data show that TGF-β1 and SCF form a positive
feedback loop that mediates the functional switch of the TGF-β
pathway to a driver of tumor progression in advanced-stage liver
cancers. Moreover, we demonstrate that TGF-β–mediated cell cycle
inhibition can be restored through disruption of the TGF-β/SCF/
STAT3 axis. Interestingly, some of the parental cell lines and their
knockdown derivatives displayed differences in their functional
behavior under baseline conditions, and the hepatoblastoma and
HCC cell lines HepG2 and Hep3B are known to differ in their p53
and Wnt/β-catenin signaling status—two of the most commonly
mutated tumor suppressor genes and oncogenic pathways in human
HCC [69–71]. However, disruption of the TGF-β/SCF/STAT3 axis
resulted in inhibition of tumor-promoting effects of TGF-β1 and
restoration of its antiproliferative functions independent of these
differences, indicating the therapeutic potential of this strategy. Our
current study provides the rationale for targeting the SCF/c-KIT/
STAT3-axis, thereby aiding the development of precision medicine
for HCC.
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